Australian regulators issue warning on Novartis' Lamisil

Share this article:
Australia's drug and medical device regulatory agency, the Therapeutic Goods Administration (TGA), has issued a warning concerning nail fungus treatment Lamisil (terbinafine) tablets following reports of three deaths and severe liver reactions among patients. 
The TGA's Adverse Drug Reactions Advisory Committee (ADRAC) received 722 adverse event reports related to Lamisil, including 70 liver reactions, 61 implicating the tablet form as the sole suspected drug.
The committee warned prescribers that the oral formulation of Lamisil should only be prescribed short-term and as a last resort.
“Oral terbinafine should be prescribed only after topical therapy has failed and for the shortest time possible, in accordance with the current product information,” the committee wrote in its drug reactions bulletin.
A spokesman for Novartis said in published reports that serious and life-threatening liver reactions were rare and well-documented side effects of oral anti-fungal medications. The company said it agreed with the advice issued by the ADRAC.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.